Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25432711 | 1.00 | PREP (0.45) | PREPRAB9AHCRTR1HCRTR2LMNA | |
| Oxalic Acid SCHEMBL25431331 | 0.99 | PREP (0.44) | PREPRAB9AHCRTR1HCRTR2LMNA | |
| SCHEMBL18801708 | 0.91 | PREP (0.43) | PREPRAB9AHCRTR1HCRTR2LMNA | |
| SCHEMBL3341710 | 0.91 | PREP (0.43) | PREPRAB9AHCRTR1HCRTR2LMNA | |
| SCHEMBL16280647 | 0.91 | PREP (0.43) | PREPRAB9AHCRTR1HCRTR2LMNA | |
| SCHEMBL3341723 | 0.91 | PREP (0.43) | PREPRAB9AHCRTR1HCRTR2LMNA | |
| SCHEMBL3341716 | 0.91 | PREP (0.43) | PREPRAB9AHCRTR1HCRTR2LMNA | |
| SCHEMBL25431326 | 0.88 | PREP (0.42) | PREPRAB9AHCRTR1HCRTR2LMNA | |
| Oxalic Acid SCHEMBL30495310 | 0.88 | CNR2 (0.44) | PREPRAB9AHCRTR1HCRTR2KMT2A | |
| SCHEMBL3342188 | 0.87 | CCR5 (0.38) | PREPLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236897-A1 | PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2025-07-24 | — | — | US | disclosed |
| EP-4479546-A2 | PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023158722-A2 | PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158722-A2 | PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-08-24 | — | — | WO | disclosed |
| US-20230102258-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-03-30 | — | — | US | disclosed |
| US-10035768-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180179160-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-06-28 | — | — | US | disclosed |
| EP-2585064-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9573897-B2 | C5AR antagonists | CHEMOCENTRYX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160229802-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-08-11 | — | — | US | disclosed |
| US-9126939-B2 | C5AR antagonists | CHEMOCENTRYX, INC. | 2015-09-08 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236897-A1 | PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF | DHPS, VARS1, AGPS | PREP 261/4885RAB9A 566/4885HCRTR1 4802/4885 |
| US-20170114017-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | PREP 597/4885RAB9A 2420/4885HCRTR1 154/4885 |
| US-20160229802-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | PREP 597/4885RAB9A 2420/4885HCRTR1 154/4885 |
| US-20180179160-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | PREP 597/4885RAB9A 2420/4885HCRTR1 154/4885 |
| US-10035768-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | PREP 597/4885RAB9A 2420/4885HCRTR1 154/4885 |
| US-20230102258-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | PREP 597/4885RAB9A 2420/4885HCRTR1 154/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | PREP 597/4885RAB9A 2420/4885HCRTR1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.